GlassScriptPhysician profile
Michael Alan Schiman
NPI 1639657729
$1,583.19
in general payments reported to CMS, 2019-2025
27 companies · $501 in 2025
The $501 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $244 · 2023: $222 · 2024: $393 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $547.28 | 2022-2025 | |
| Boston Scientific Corporation | $78.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $75.21 | 2023-2024 | |
| Biogen, INC. | $74.24 | 2021-2025 | Tysabri, Vumerity, Skyclarys |
| Sk Life Science, INC. | $69.76 | 2021-2024 | |
| Eisai INC. | $65.43 | 2023-2024 | |
| Genentech USA, INC. | $65.35 | 2024-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Janssen Pharmaceuticals, INC | $60.30 | 2021 | |
| Argenx US, INC. | $58.75 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Biohaven Pharmaceutical Holding Company LTD. | $52.60 | 2022 | |
| Lilly USA, LLC | $50.21 | 2023-2025 | Amyvid, Kisunla |
| Pfizer INC. | $41.14 | 2021-2025 | |
| Emd Serono, INC. | $37.30 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $37.08 | 2022-2023 | Rytary |
| Tg Therapeutics, INC. | $35.58 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.40 | 2021-2022 | |
| Janssen Biotech, INC. | $29.34 | 2025 | |
| Celgene Corporation | $20.59 | 2023 | Zeposia |
| Cycle Pharmaceuticals INC | $20.51 | 2025 | Bafiertam, Tascenso Odt |
| Teva Pharmaceuticals USA, INC. | $20.17 | 2024 | Ajovy |
| Aucta Pharmaceuticals, INC. | $19.20 | 2024 | Motpoly Xr |
| Otsuka America Pharmaceutical, INC. | $17.98 | 2025 | Rexulti |
| Lundbeck LLC | $17.86 | 2021 | |
| Kyowa Kirin, INC. | $16.45 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.57 | 2021 | |
| Neurelis, INC. | $14.60 | 2021 | |
| Ucb, INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.